Skip to main content
WUHAN HVSEN BIOTECHNOLOGY CO.,LTD. logo

WUHAN HVSEN BIOTECHNOLOGY CO.,LTD. — Investor Relations & Filings

Ticker · 300871 ISIN · CNE1000047H6 Shenzhen Stock Exchange Manufacturing
Filings indexed 1,018 across all filing types
Latest filing 2026-05-22 Share Issue/Capital Cha…
Country CN China
Listing Shenzhen Stock Exchange 300871

About WUHAN HVSEN BIOTECHNOLOGY CO.,LTD.

https://www.whhsyy.com

Wuhan Hvsen Biotechnology Co., Ltd. specializes in the research, development, manufacturing, and distribution of veterinary pharmaceuticals and animal health solutions. The company's product portfolio includes a wide range of veterinary drugs such as antibiotics, antiparasitics, and anti-inflammatory agents, alongside vaccines, feed additives, and specialized disinfectants. Hvsen Biotechnology focuses on enhancing livestock productivity and animal welfare, primarily serving the swine, poultry, and cattle industries. Operating with advanced GMP-certified production facilities, the company emphasizes technological innovation and quality control to meet international standards. Its business model integrates scientific research with industrial application, providing comprehensive health management programs for large-scale farming operations and global distribution networks.

Recent filings

Filing Released Lang Actions
关于收到深圳证券交易所终止对公司申请向特定对象发行股票审核决定的公告
Share Issue/Capital Change Classification · 78% confidence The document is an official announcement by Wuhan Huisheng Biotechnology Co., Ltd. informing shareholders that the Shenzhen Stock Exchange has decided to terminate its review of the company’s application to issue A-shares to specific investors. This is not a full financial report or earnings release, but a capital change notification concerning share issuance. Therefore, it fits the “Share Issue/Capital Change” category (SHA).
2026-05-22 Chinese
关于完成注册资本、经营范围变更登记并换发营业执照的公告
Share Issue/Capital Change Classification · 85% confidence The document is an official corporate announcement by Wuhan Huisheng Biotechnology Co., Ltd. regarding the completion of a registration capital change (cancellation of repurchased shares and adjustment of registered capital) and business scope amendment, followed by issuance of a new business license. It does not present financial statements or management discussion, but specifically communicates a capital change event. This aligns with the “Share Issue/Capital Change” category (SHA).
2026-05-13 Chinese
国浩律师(深圳)事务所关于武汉回盛生物科技股份有限公司2025年度股东会法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a legal opinion letter issued by a law firm regarding the legality of the convening, attendance, voting procedures, and results of the 2025 Annual General Meeting (AGM) of Wuhan Huisheng Biotechnology Co., Ltd. It details the meeting date, voting results on various proposals, and confirms the compliance of the meeting with relevant laws and company bylaws. The document does not contain the actual annual report or financial statements but rather certifies the AGM process and voting outcomes. This fits the definition of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results of the AGM.
2026-05-08 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a "2025年年度股东会决议公告" which translates to "2025 Annual General Meeting (AGM) Resolution Announcement." It details the date, attendance, voting results on various proposals including the 2025 annual report, financial statements, profit distribution, director remuneration, and auditor appointment. The document is a formal announcement of the resolutions passed at the AGM, including voting outcomes and legal opinions confirming the validity of the meeting and resolutions. It does not contain the full annual report or financial statements themselves but reports on the meeting decisions and voting results. The document length is 3260 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-08 Chinese
2025年度会计师事务所履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an evaluation report on the performance of the accounting firm for the fiscal year 2025. It details the auditor's qualifications, audit team members, independence, and the audit work performed for the 2025 fiscal year, including the issuance of audit reports. The document is an assessment of the auditor's performance rather than the audit report itself or the full annual report. It is a standalone audit-related report focusing on the auditor's role and compliance with auditing standards. The document length is about 2023 characters, which is relatively short but contains substantive content about the audit firm's performance and evaluation, not just an announcement or certification. Therefore, it fits best under the category of Audit Report / Information (AR).
2026-04-16 Chinese
关于举办2025年度网上业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of an upcoming online earnings presentation (业绩说明会) for the 2025 fiscal year. It references the prior publication of the 2025 Annual Report but does not contain financial data or the report itself. The document is short (1130 characters) and serves to inform investors about the time, place, and participation method for the earnings explanation meeting. This fits the definition of an Investor Presentation announcement rather than the presentation or report itself. Therefore, the correct classification is Investor Presentation (IP).
2026-04-16 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.